Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
26
07
2021
accepted:
02
08
2021
revised:
29
07
2021
pubmed:
21
8
2021
medline:
16
2
2022
entrez:
20
8
2021
Statut:
ppublish
Résumé
We sought to determine the relationship between age-related clonal hematopoiesis (CH) and chronic kidney disease (CKD). CH, defined as mosaic chromosome abnormalities (mCA) and/or driver mutations was identified in 5449 (2.9%) eligible UK Biobank participants (n = 190,487 median age = 58 years). CH was negatively associated with glomerular filtration rate estimated from cystatin-C (eGFR.cys; β = -0.75, P = 2.37 × 10
Identifiants
pubmed: 34413458
doi: 10.1038/s41375-021-01382-3
pii: 10.1038/s41375-021-01382-3
pmc: PMC8807385
mid: EMS132518
doi:
Substances chimiques
CST3 protein, human
0
Cystatin C
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
507-515Subventions
Organisme : Blood Cancer UK
ID : 13002
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.
pubmed: 25426838
pmcid: 4290021
doi: 10.1056/NEJMoa1409405
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.
pubmed: 25426837
pmcid: 4306669
doi: 10.1056/NEJMoa1408617
Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44:651.
pubmed: 22561519
pmcid: 3372921
doi: 10.1038/ng.2270
Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44:642.
pubmed: 22561516
pmcid: 3366033
doi: 10.1038/ng.2271
Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16.
pubmed: 25931582
pmcid: 4624443
doi: 10.1182/blood-2015-03-631747
Zekavat SM, Lin S-H, Bick AG, Liu A, Paruchuri K, Wang C, et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat. Med. 2021;27:1012–24.
Bick AG, Popadin K, Thorball CW, Uddin MM, Zanni M, Yu B, et al. Increased CHIP prevalence amongst people living with HIV. MedRxiv: 11.06.20225607 [Preprint]. 2020.
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21.
pubmed: 28636844
pmcid: 6717509
doi: 10.1056/NEJMoa1701719
Buscarlet M, Provost S, Zada YF, Barhdadi A, Bourgoin V, Lépine G, et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017;130:753–62.
pubmed: 28655780
doi: 10.1182/blood-2017-04-777029
Honigberg MC, Zekavat SM, Niroula A, Griffin GK, Bick AG, Pirruccello JP, et al. Premature menopause, clonal hematopoiesis, and coronary artery disease in postmenopausal women. Circulation. 2021;143:410–23.
pubmed: 33161765
doi: 10.1161/CIRCULATIONAHA.120.051775
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.
pubmed: 23727169
doi: 10.1016/S0140-6736(13)60687-X
Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation. 2003;108:2154–69.
pubmed: 14581387
doi: 10.1161/01.CIR.0000095676.90936.80
Levey AS, Coresh J, Bolton K, Culleton B, Harvey KS, Ikizler TA, et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
Group KDIGOCW. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
Israni A, Snyder J, Skeans M, Peng Y, Maclean J, Weinhandl E, et al. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant. 2010;10:338–53.
pubmed: 20415903
doi: 10.1111/j.1600-6143.2009.02949.x
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52.
pubmed: 23727170
doi: 10.1016/S0140-6736(13)60595-4
Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 1996;7:158–65.
pubmed: 8808124
doi: 10.1681/ASN.V71158
Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165–80.
pubmed: 21840587
doi: 10.1016/S0140-6736(11)60178-5
Oberg BP, McMenamin E, Lucas F, McMonagle E, Morrow J, Ikizler T, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009–16.
pubmed: 14871421
doi: 10.1111/j.1523-1755.2004.00465.x
Busque L, Sun M, Buscarlet M, Ayachi S, Zada YF, Provost S, et al. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2020;4:2430.
pubmed: 32492156
pmcid: 7284088
doi: 10.1182/bloodadvances.2019000770
Hojs R, Ekart R, Bevc S, Hojs N. Markers of inflammation and oxidative stress in the development and progression of renal disease in diabetic patients. Nephron. 2016;133:159–62.
pubmed: 27344598
doi: 10.1159/000447434
Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res. 2018;2018:2180373.
pubmed: 30271792
pmcid: 6146775
doi: 10.1155/2018/2180373
Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203.
pubmed: 30305743
pmcid: 6786975
doi: 10.1038/s41586-018-0579-z
Szustakowski JD, Balasubramanian S, Kvikstad E, Khalid S, Bronson PG, Sasson A, et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat. Genet. 2021;53:942–8.
Dawoud AAZ, Tapper WJ, Cross NCP. Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia. 2020;34:2660–72.
pubmed: 32518416
doi: 10.1038/s41375-020-0896-8
Pattaro C, Riegler P, Stifter G, Modenese M, Minelli C, Pramstaller PP. Estimating the glomerular filtration rate in the general population using different equations: effects on classification and association. Nephron Clin Pract. 2013;123:102–11.
pubmed: 23797027
doi: 10.1159/000351043
Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
pubmed: 19414839
pmcid: 2763564
doi: 10.7326/0003-4819-150-9-200905050-00006
Grubb A. Shrunken pore syndrome—a common kidney disorder with high mortality. Diagnosis, prevalence, pathophysiology and treatment options. Clin Biochem. 2020;83:12–20.
pubmed: 32544475
doi: 10.1016/j.clinbiochem.2020.06.002
Kdigo A. Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
Smith GD, Davies NM, Dimou N, Egger M, Gallo V, Golub R, et al. STROBE-MR: guidelines for strengthening the reporting of Mendelian randomization studies: PeerJ Preprints; 2019. Report no. 2167-9843.
Bick AG, Weinstock JS, Nandakumar SK, Fulco CP, Bao EL, Zekavat SM, et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature. 2020;586:763–8.
pubmed: 33057201
pmcid: 7944936
doi: 10.1038/s41586-020-2819-2
Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet. 2019;51:957.
pubmed: 31152163
pmcid: 6698888
doi: 10.1038/s41588-019-0407-x
Burgess S, Smith GD, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res. 2019;4.
Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.
pubmed: 29846171
pmcid: 5976434
doi: 10.7554/eLife.34408
Zhao Q, Wang J, Hemani G, Bowden J, Small DS. Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. Ann Stat. 2020;48:1742–69.
doi: 10.1214/19-AOS1866
Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37:658–65.
pubmed: 24114802
pmcid: 4377079
doi: 10.1002/gepi.21758
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512–25.
pubmed: 26050253
pmcid: 4469799
doi: 10.1093/ije/dyv080
Bowden J, Davey, Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40:304–14.
pubmed: 27061298
pmcid: 4849733
doi: 10.1002/gepi.21965
Therneau TM, Grambsch PM. The Cox Model. In: Therneau TM, Grambsch PM (eds). Modeling Survival Data: Extending the Cox Model. Springer New York: New York, NY, 2000, pp 39–77.
Grolemund G, Wickham H. Dates and times made easy with lubridate. J Stat Softw. 2011;40:1–25.
doi: 10.18637/jss.v040.i03
Croxford R Restricted cubic spline regression: a brief introduction. Toronto: Institute for Clin Eval Sci 2016:1–5.
Harrell Jr FE. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Springer, Cham;; 2015.
Bradley AP. The use of the area under the ROC curve in the evaluation of machine learning algorithms. Pattern Recognit. 1997;30:1145–59.
doi: 10.1016/S0031-3203(96)00142-2
Dawoud AAZ, Tapper WJ, Cross NCP. Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia. 2020;34:2660–72.
Lees JS, Welsh CE, Celis-Morales CA, Mackay D, Lewsey J, Gray SR, et al. Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nat Med. 2019;25:1753–60.
pubmed: 31700174
pmcid: 6858876
doi: 10.1038/s41591-019-0627-8
Bick AG, Pirruccello JP, Griffin GK, Gupta N, Gabriel S, Saleheen D, et al. Genetic Interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation. 2020;141:124–31.
pubmed: 31707836
doi: 10.1161/CIRCULATIONAHA.119.044362
Pedersen KM, Çolak Y, Ellervik C, Hasselbalch HC, Bojesen SE, Nordestgaard BG. Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study. EClinicalMedicine 2020;21:100280.
Grubb A. Cystatin C is indispensable for evaluation of kidney disease. eJIFCC. 2017;28:268–76.
pubmed: 29333146
pmcid: 5746836
Nowak C, Ärnlöv J. Kidney disease biomarkers improve heart failure risk prediction in the general population. Circulation. 2020;13:e006904.
pubmed: 32757644
Zi M, Xu Y. Involvement of cystatin C in immunity and apoptosis. Immunol Lett. 2018;196:80–90.
pubmed: 29355583
pmcid: 7112947
doi: 10.1016/j.imlet.2018.01.006
Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis. 2008;51:212–23.
pubmed: 18215699
pmcid: 4083633
doi: 10.1053/j.ajkd.2007.10.035
Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–58.
pubmed: 9987089
doi: 10.1046/j.1523-1755.1999.00273.x
Christensen AS, Møller JB, Hasselbalch HC. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2014;38:490–5.
pubmed: 24630365
doi: 10.1016/j.leukres.2014.01.014
Koschmieder S, Chatain N. Role of inflammation in the biology of myeloproliferative neoplasms. Blood Rev. 2020;42:100711.
pubmed: 32505517
doi: 10.1016/j.blre.2020.100711
Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat. Genet. 2021;53:185–94.
Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science 2019;366.